RemeGen launches $514m Hong Kong listing

Jonathan Breen

October 28, 2020 05:45 AM

RemeGen, a Chinese biopharmaceutical company, has rolled out a Hong Kong IPO that could be worth up to HK$3.99bn ($514.5m).

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP Morgan Equity IPOs Health and Biotech UBS Equity China Hong Kong SAR Asia Greater China Bank of Communications Haitong Securities Morgan Stanley Northeast Asia Asia Pacific Emerging Markets SRI

JB

Jonathan Breen

Equities editor GlobalCapital Asia